Published on 29 January 2015

2014/4 GaBI Journal Table of Contents

Contents Editor’s Letter Fourth and final issue of GaBI Journal’s third volume Editorial Availability and procurement of generics in hospitals among medium-sized European countries Letters to the Editor Access to alternative biopharmaceuticals in low- and middle- income countries Commentary Biosimilars versus ‘biobetters’ — a regulator’s perspective Original Research Availability and procurement conditions of originator and…

---

Published on 01 January 2018

2017/4 GaBI Journal Table of Contents

Contents Editor’s Letter Fourth and final issue of GaBI Journal’s sixth volume Letters to the Editor Clear naming, traceability of biological medicines will protect patients Comment on the non-biological complex drugs paper Commentary Global policies on pharmacy-mediated substitution of biosimilars: a summary Original Research Pharmacy-mediated substitution of biosimilars – a global survey benchmarking country substitution…

---

Original Research

Published on 23 March 2026

Real-world evaluation of dosing and haemoglobin A1c (HbA1c) in patients converted from insulin glargine (Lantus®) to insulin glargine (Basaglar®) in Saudi Arabia 

Introduction/Study objective: About 28% of Saudi Arabia population above 15 years old are diagnosed with diabetes. Basal insulin glargine Lantus and its’ biosimilar Basaglar, are long-acting insulin that regulate blood glucose levels over 24 hours. Patients switch between basal insulins for various reasons including adverse events, availability and cost. Switching should be done with careful…

Author(s): Salwa Almomen, MD, MSc, Fares Alrubaish, PharmD, Radwan Hafiz, PharmD, Ali M Alhomaidan, PhD

biosimilars, HbA1c, interchangeability, long-acting insulin analogues, switching, treatment conversion

DOI: 10.5639/gabij.2026.1501.

---

Published on 16 October 2014

2012/1 GaBI Journal Table of Contents

Contents Editor's Letter Introduction to the GaBI Journal Editorial Generic medicine pricing: on track in Europe? Commentary Innovator companies should focus on innovations Review Article A review of generic medicine pricing in Europe Biologicals and biosimilars: a review of the science and its implications A patient-centred paradigm for the biosimilars market European payer initiatives to…

---

Thank you to reviewers

Published on 09 March 2021

Thank you to reviewers 2020

The editors and publisher wish to express their gratitude to the colleagues listed below for their valuable contribution to the peer review process for the Generics and Biosimilars Initiative Journal (GaBI Journal) in 2020. Dr Adel AL Harf, Saudi Arabia Professor Alain Astier, France Professor Moses SS Chow, USA Dr Alessandro Curto, Italy Professor Theodor…

---